India Biosimilar Market Trends 2025: Size, Share, Growth Rate, Research Report 2033

As indicated in the latest market research report published by IMARC Group, titled "India Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, Others), Indication (Auto-Immune Diseases, Blood Disorders, Diabetes, Oncology, Growth Deficiency, Female Infertility, Others), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Region 2025-2033," this report provides an in-depth analysis of the industry, featuring insights into the market. It encompasses competitor and regional analyses, as well as recent advancements in the market.

Market Size & Future Growth Potential

The India biosimilar market size reached USD 866.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,662.9 Million by 2033, exhibiting a growth rate (CAGR) of 17.38% during 2025-2033.

Trends – India Biosimilar Market

The India biosimilar market is experiencing significant transformation, driven by increasing demand for affordable biologics and expanding healthcare accessibility across the country. Trends in this sector highlight the growing adoption of biosimilars as cost-effective alternatives to branded biologics, especially in the treatment of chronic and life-threatening conditions such as cancer, autoimmune disorders, and diabetes. Additionally, rising investments in research and development, coupled with government initiatives to promote domestic manufacturing, are shaping the industry’s trajectory. 

Moreover, the entry of established pharmaceutical companies and the rise of strategic collaborations with global firms are enhancing market competitiveness and accelerating innovation. In addition, the growing acceptance of biosimilars among healthcare professionals and patients is boosting their integration into mainstream medical practice. Increasing awareness campaigns, improved regulatory frameworks, and a strong emphasis on quality compliance further contribute to the market’s positive outlook. As India strengthens its position as a leading hub for biosimilar production, these evolving trends underline the country’s potential to not only meet domestic healthcare needs but also cater to international markets seeking affordable therapeutic solutions.

Scope and Growth Analysis – India Biosimilar Market

The scope of the India biosimilar market continues to expand as pharmaceutical companies focus on developing a wide range of therapies to address unmet medical needs. The market growth is being propelled by factors such as the rising prevalence of chronic diseases, advancements in biotechnology, and favorable government support to encourage innovation and local manufacturing. Additionally, the cost-effectiveness of biosimilars compared to biologics makes them highly attractive for patients and healthcare providers, thereby widening their adoption rate. 

Moreover, the increasing number of patent expirations of blockbuster biologics creates lucrative opportunities for Indian firms to strengthen their portfolios and establish themselves as global leaders in biosimilar production. In addition, improvements in clinical trial infrastructure, regulatory harmonization, and technological advancements in bioprocessing are fostering faster approvals and efficient production processes. The export potential of India’s biosimilar industry is also notable, with international demand for affordable biologics on the rise. With continuous emphasis on quality, innovation, and affordability, the India biosimilar market is poised for robust expansion, positioning the country as a critical player in shaping the global biosimilar landscape.

Request Free Sample Report: https://www.imarcgroup.com/india-biosimilar-market/requestsample

Comprehensive Market Report Highlights & Segmentation Analysis

Segmentation by Molecule:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Pegfilgrastim
• Trastuzumab
• Bevacizumab
• Others

Segmentation by Indication:

• Auto-Immune Diseases
• Blood Disorders
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Others

Segmentation by Manufacturing Type:

• In-house Manufacturing
• Contract Manufacturing

Segmentation by Region:

• North India
• West and Central India
• South India
• East and Northeast India

Recent News and Developments:

• Regulatory Milestones: The Central Drugs Standard Control Organisation (CDSCO) revised biosimilar guidelines in 2024, streamlining approval processes and reducing development timelines for domestic manufacturers.
• Manufacturing Investments: Major Indian pharmaceutical companies announced capital investments exceeding USD 45-50 million for new biosimilar manufacturing facilities, focusing on oncology and autoimmune therapeutic areas.
• Patent Cliff Opportunities: Over 55 blockbuster biologics worth billions in revenue are scheduled to lose patent protection, creating substantial market opportunities for Indian biosimilar manufacturers.
• Export Expansion: Indian biosimilar manufacturers secured approvals in regulated markets including Europe and North America, with several products launching in international markets during 2024.
• Government Policy Support: The Department of Biotechnology announced new incentive schemes specifically targeting biosimilar development, including funding support for clinical trials and manufacturing scale-up.
• Strategic Partnerships: Leading Indian pharmaceutical companies entered into strategic alliances with global biopharmaceutical companies for technology transfer and co-development of complex biosimilars.
• Legal Developments: Delhi High Court rulings in 2024 regarding biosimilar patent disputes have clarified intellectual property frameworks, providing greater certainty for market participants.
• Manufacturing Capacity: Indian contract manufacturing organizations expanded biosimilar production capabilities, with new facilities coming online to meet growing domestic and export demand.
• Clinical Trial Approvals: CDSCO approved multiple Phase III clinical trials for next-generation biosimilars in oncology and autoimmune indications, signaling robust pipeline development.
• Market Access Initiatives: Government healthcare schemes expanded coverage for biosimilar therapies, improving patient access and driving volume growth across therapeutic categories.

Competitor Landscape:

The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.

Explore the Full Report with Charts, Table of Contents, and List of Figures: https://www.imarcgroup.com/india-biosimilar-market

Key Highlights of the Report

• Historical Market Performance
• Future Market Projections
• Impact of COVID-19 on Market Dynamics
• Industry Competitive Analysis (Porter's Five Forces)
• Market Dynamics and Growth Drivers
• SWOT Analysis (Strengths, Weaknesses, Opportunities, Threats)
• Market Ecosystem and Value Creation Framework
• Competitive Positioning and Benchmarking Strategies

Major Advantages of the Report:

• This report provides market leaders and new entrants with accurate revenue estimates for the overall market and its key subsegments.
• Stakeholders can leverage this report to gain a deeper understanding of the competitive landscape, enabling them to strategically position their businesses and develop effective go-to-market strategies.
• The report provides stakeholders with valuable insights into the market dynamics, offering a comprehensive analysis of key drivers, restraints, challenges, and opportunities.

Why Choose IMARC Group:

• Extensive Industry Expertise
• Robust Research Methodology
• Insightful Data-Driven Analysis
• Precise Forecasting Capabilities
• Established Track Record of Success
• Reach with an Extensive Network
• Tailored Solutions to Meet Client Needs
• Commitment to Strong Client Relationships and Focus
• Timely Project Delivery
• Cost-Effective Service Options

Note: Should you require specific information not included in the current report, we are pleased to offer customization options to meet your needs.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Contact US

IMARC Group 134 N 4th St. Brooklyn, NY 11249, USA Email: Sales@imarcgroup.com Tel No:(D) +91 120 433 0800 Americas: +1-201971-6302 | Africa and Europe: +44-702-409-7331